E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 Diabetes in Overweight and Obese Patients |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 Diabetes in Overweight and Obese Patients |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess the effect of MEDI0382 on glucose control and body weight from baseline to the end of a 4-week treatment period at a stable dose (end of treatment). |
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives: 1. To assess the effect of MEDI0382 on glucose control as measured by the standardized Mixed Meal Test (MMT), HbA1c, and fructosamine data from baseline through end of treatment 2. To characterize the safety profile of MEDI0382 following subcutaneous (SC) administration of multiple-ascending doses (MADs) 3. To characterize the pharmacokinetics (PK) and immunogenicity (IM) of MEDI0382 4. To characterize the pharmacodynamics (PD) effect of MEDI0382 on glucose metabolism following a MMT |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Male or female age 18-65 -Must provide written informed consent -Body mass index 27 to 40 kg/m2 -Vital signs within normal specified ranges -Diagnosis of T2DM and glucose control managed with metformin monotherapy where no significant dose change has occurred in the 3 months prior to screening. -Venous access suitable for multiple cannulations. -For subjects in Cohort 4, 5 and 6: Willing and able to self-administer daily SC injections. -Females must be non-lactating and non-childbearing potential -Males must practice 2 effective contraceptive measures if sexually active
|
|
E.4 | Principal exclusion criteria |
-Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product -History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs -History of cancer within the last 10 years, with the exception of non-melanoma skin cancer -History or presence of diabetic foot ulcers -Any clinically important illness (apart from T2DM for subjects with known diabetes), medical/ surgical procedure, or trauma within 4 weeks prior to Day 1 dosing. -Symptoms of insulinopenia or poor blood glucose control - Fasting blood glucose ≥ 200 mg/dL -Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at screening. -Use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited. -Known or suspected history of alcohol or drug abuse within the past 3 years. Positive drug screen. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoints (Cohort 4 only): • Change from baseline in glucose AUC (up to 240 minutes post-MMT) to end of treatment • Change from baseline in body weight in kg to end of treatment |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary Endpoints: • Change from baseline in HbA1c and fructosamine and percent change in 24-hour glucose AUC post-MMT through end of treatment • Percent change from baseline in MMT glucose AUC (up to 240 minutes post-MMT) to end of treatment • Change from baseline in body weight in kg to end of treatment • Adverse events (AEs) • Blood Pressure (BP) • Pulse • Safety laboratory test results • ECG findings • Columbia-Suicide Severity Rating Scale score (cohort 4) • PK endpoints for MEDI0382: AUC over a dosing duration, maximum observed concentration (Cmax), minimum observed concentration, time to maximum observed concentration (Tmax)(all cohorts); terminal half-life, and accumulation ratio (Cohorts 1 to 3 only) • Concentration of Metformin • Development of antidrug antibody (ADA) and titer (if positive) • PD endpoints (glucose metabolism panel): ◦ Glucose ◦ Beta cell health: insulin, pro-insulin, and c-peptide ◦ Incretins: GLP-1, glucagon, gastric inhibitory peptide (GIP) ◦ Cohorts 5 and 6 insulin and glucose only |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Last study visit- Follow up, 28 days post last study visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study ("study completion") is defined as the date of the last protocol-specified visit/assessment (including telephone contact) for the last subject in the study.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |